SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.590
-0.030 (-1.85%)
At close: Aug 6, 2025, 4:00 PM
1.600
+0.010 (0.61%)
After-hours: Aug 6, 2025, 7:01 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Theseus Pharmaceuticals stock has a target of 7.00, which predicts a 340.25% increase from the current stock price of 1.59.
Price Target: $7.00 (+340.25%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Theseus Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +340.25% | Jul 16, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $3 | Buy | Reiterates | $3 | +88.68% | Nov 22, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $3 | Buy | Reiterates | $3 | +88.68% | Sep 7, 2023 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $14 → $8 | Strong Buy | Maintains | $14 → $8 | +403.14% | Nov 15, 2022 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +277.36% | Jun 28, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
10.95M
EPS This Year
-0.35
from -0.50
EPS Next Year
-0.41
from -0.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 22.8M | 46.5M | ||
| Avg | n/a | 10.9M | 44.7M | ||
| Low | n/a | n/a | 43.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 324.3% | ||
| Avg | - | - | 308.2% | ||
| Low | - | - | 296.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.26 | -0.32 | 0.27 | ||
| Avg | -0.35 | -0.41 | -0.14 | ||
| Low | -0.49 | -0.52 | -0.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.